To investigate whether the reduced tumor growth in GPR182−/− mice was due to improved antitumor T cell response, we depleted CD4+ and CD8+ T cells in GPR182−/− and WT mice by intraperitoneal injection of anti-CD4 and anti-CD8β depleting mAbs together. The gene discussed is CD8A; the disease is neoplasm.